New data have also demonstrated that antibodies targeting IL-6/IL-6R/gp130 such as tocilizumab, siltuximab and clazakizumab could be employed for the therapy of COVID-19 [122,123,124,125], as was also recommended by the National Institute of Health (NIH COVID-19 Treatment Guidelines, 2020) [126]. Here, IL6 is linked to COVID-19.